营收同比下降33.8%,基石药业押注三抗管线进展如何?

21世纪经济报道
Apr 01

继2024年上半年首次实现盈利、全年财务业绩持续改善后,基石药业(2616.HK)2025年业绩再度下滑。年报显示,公司2025年实现收入2.7亿元,同比下降33.8%;年内亏损扩大至4.37亿元,较2024年的0.91亿元亏损增加3.46亿元。  在业绩承压的背景下,基石药业同步披露了PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新开发进展及I/II期关键临床数据。基石药业首席...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10